Genewiz, a provider of DNA services, has obtained clinical laboratory improvement amendments (CLIA) certification.
The certification allows the company to expand its clinical genomic testing solutions, thus contributing to advancements in personalized medicine.
Genewiz vice president Conrad Leung said with CLIA registration, the company now has the capacity to provide comprehensive solutions for clients working in clinical environments.
"We are committed to providing clinical researchers, physicians, and patients with genomic testing results that ultimately lead to better diagnoses and more effective treatments," Leung added.
Genewiz intends to develop additional CLIA-certified assays by using its conventional platforms and next generation sequencing technology.
The company recently expanded laboratory operations in South Plainfield, New Jersey, US, to include a clean suite designed for processing clinical and pre-clinical samples.
The laboratory allows the company to provide expanded services in the areas of biologic drug and cell bank characterization testing, clinical trial investigations, and clinical diagnostic testing.